WinstonWınston
Linike Medical Group logo

Linike Medical Group

LNMG
49
Specialty Retail · Consumer Cyclical
Price
$0.01
+0.00 (+0.00%)
Market Cap
$3.5M
Winston Score
49
Winston is serious
Mixed quality — meaningful strengths and weaknesses.

Share count rising — dilution

+31.3% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 509.5M (2021) → 668.9M (2025)

Linike Medical Group Ltd (ticker: LNMG) does not appear in widely available public financial databases, and there is very little verifiable information about its operations, products, or customers. The company is classified under Shell Companies within the Financial Services sector, which means it may be a holding company, a blank-check entity, or a vehicle in the process of acquiring or merging with an operating business. Without confirmed details, describing its core products or end markets with accuracy is not possible.

The company carries a market cap near zero, suggesting it is extremely small or thinly traded. Its gross margin of 58.2% and operating margin of 16.5% hint that some revenue-generating activity may exist, but the very low ROIC of 1.1% indicates capital is not being used efficiently. Shell companies in this classification carry significant risks for investors, including limited transparency, sparse regulatory filings, and uncertainty about what the underlying business actually is or will become.

Winston Score History

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
92.3%
Premium pricing power — 92.3% gross margin
Operating Margin
10.0%
Modest — 10.0% operating margin
ROCE
0.4%
Weak — 0.4% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
-4.9%
Shrinking sales (-4.9% YoY)
EPS YoY
N/A
Data not available
EPS Consistency
6/8 quarters
Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
-52%
Weak — only -52% of profit becomes cash
FCF Margin
-21.7%
Burning cash (-21.7%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.45
Conservative — low debt load (0.45)
Interest Cover
100.00x
Comfortably covers interest (100.0x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
1.4x
Attractive valuation — P/E 1.4

P/E under 10. The price tag is small relative to last year's profit.

P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial